CA2874646C - Non-natural consensus albumin binding domains - Google Patents

Non-natural consensus albumin binding domains Download PDF

Info

Publication number
CA2874646C
CA2874646C CA2874646A CA2874646A CA2874646C CA 2874646 C CA2874646 C CA 2874646C CA 2874646 A CA2874646 A CA 2874646A CA 2874646 A CA2874646 A CA 2874646A CA 2874646 C CA2874646 C CA 2874646C
Authority
CA
Canada
Prior art keywords
albumin binding
binding domain
seq
isolated
abdcon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2874646A
Other languages
English (en)
French (fr)
Other versions
CA2874646A1 (en
Inventor
Steven Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CA2874646A1 publication Critical patent/CA2874646A1/en
Application granted granted Critical
Publication of CA2874646C publication Critical patent/CA2874646C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2874646A 2012-05-25 2013-05-23 Non-natural consensus albumin binding domains Active CA2874646C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651642P 2012-05-25 2012-05-25
US61/651,642 2012-05-25
US201361776918P 2013-03-12 2013-03-12
US61/776,918 2013-03-12
PCT/US2013/042429 WO2013177398A2 (en) 2012-05-25 2013-05-23 Non-natural consensus albumin binding domains

Publications (2)

Publication Number Publication Date
CA2874646A1 CA2874646A1 (en) 2013-11-28
CA2874646C true CA2874646C (en) 2020-12-01

Family

ID=49622071

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2874646A Active CA2874646C (en) 2012-05-25 2013-05-23 Non-natural consensus albumin binding domains

Country Status (15)

Country Link
US (3) US9156887B2 (https=)
EP (1) EP2855509B1 (https=)
JP (3) JP2015519345A (https=)
KR (1) KR102053674B1 (https=)
CN (1) CN104470944B (https=)
AU (2) AU2013266215B2 (https=)
BR (1) BR112014029409B1 (https=)
CA (1) CA2874646C (https=)
DK (1) DK2855509T3 (https=)
EA (1) EA036487B1 (https=)
ES (1) ES2670442T3 (https=)
IL (2) IL235808A (https=)
MX (1) MX355041B (https=)
PT (1) PT2855509T (https=)
WO (1) WO2013177398A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CN105247118A (zh) * 2013-03-14 2016-01-13 多伦多大学管理委员会 支架化肽文库以及其制备和筛选方法
CA2979973A1 (en) * 2015-04-29 2016-11-03 Mediolanum Farmaceutici S.P.A. A soluble chimeric interleukin-10 receptor and therapeutic use thereof
WO2016204884A1 (en) * 2015-06-18 2016-12-22 Albert Einstein College Of Medicine, Inc. Fgf receptor ligands for treating diabetes and obesity
EP3374504B1 (en) * 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
CN106699842B (zh) * 2015-11-17 2020-06-12 上海交通大学 一种新的抗炎小分子多肽及其应用
EP3423480A1 (en) 2016-03-01 2019-01-09 The Board of Trustees of the University of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
NZ754187A (en) 2016-12-14 2026-02-27 Janssen Biotech Inc Cd8a-binding fibronectin type iii domains
WO2018140456A1 (en) 2017-01-24 2018-08-02 Northwestern University Active low molecular weight variants of angiotensin converting enzyme 2 (ace2)
EP3664832B1 (en) 2017-08-11 2023-10-18 The Board of Trustees of the University of Illinois Truncated guinea pig l-asparaginase variants and methods of use
EP3765496A1 (en) 2018-03-13 2021-01-20 Affibody AB Polypeptides based on a novel scaffold
KR102282240B1 (ko) * 2018-12-06 2021-07-28 경상국립대학교산학협력단 지속형 엑센딘-4 및 이의 용도
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
WO2021127353A1 (en) 2019-12-18 2021-06-24 Aro Biotherapeutics Company Serum albumin-binding fibronectin type iii domains and uses thereof
US12123036B2 (en) 2020-02-26 2024-10-22 Northwestern University Soluble ACE2 variants and uses therefor
EP4148126A4 (en) * 2020-03-25 2025-01-08 Curigin Co.,Ltd. ANTI-TUMOR ADENOVIRUS IMMUNO-EVASIVE
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
CN113336860B (zh) * 2021-06-02 2022-07-01 北京大学 一种具有靶向和长效功能的重组水蛭素融合蛋白及其编码基因和应用
JP2025538292A (ja) * 2022-11-09 2025-11-27 レプリゲン・コーポレーション 親和性剤
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025125378A1 (en) * 2023-12-12 2025-06-19 Navigo Proteins Gmbh Novel serum albumin-binding fusion proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
AU672794B2 (en) * 1992-05-07 1996-10-17 Affitech As Immunoglobulin binding proteins derived from L protein and their uses
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
PT1538206E (pt) 1997-09-16 2010-04-12 Centocor Ortho Biotech Inc Método para a síntese química e construção completa de genes e genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2694139C (en) 2007-07-31 2018-06-05 Affibody Ab Albumin binding polypeptide compositions
KR20110039220A (ko) 2008-06-30 2011-04-15 교와 핫꼬 기린 가부시키가이샤 항ｃｄ27 항체
BRPI0919881B1 (pt) * 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
US8580274B2 (en) * 2009-02-10 2013-11-12 University Of The Ryukyus Drug transporter, and adjuvant and vaccine each utilizing same
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
WO2010141329A1 (en) * 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
EP3165540A1 (en) 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antibodies that bind human cd27 and uses thereof
EP3569256B1 (en) 2010-04-30 2022-06-15 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
AU2013266215B2 (en) 2017-12-07
JP2021019595A (ja) 2021-02-18
IL254652A0 (en) 2017-11-30
AU2017261625A1 (en) 2017-12-07
CN104470944B (zh) 2021-09-14
AU2017261625B2 (en) 2019-11-21
IL254652B (en) 2019-12-31
DK2855509T3 (en) 2018-07-23
EP2855509A2 (en) 2015-04-08
KR102053674B1 (ko) 2019-12-09
CA2874646A1 (en) 2013-11-28
US10280200B2 (en) 2019-05-07
WO2013177398A2 (en) 2013-11-28
KR20150016585A (ko) 2015-02-12
EA036487B1 (ru) 2020-11-16
US20130316952A1 (en) 2013-11-28
IL235808A0 (en) 2015-01-29
US9156887B2 (en) 2015-10-13
CN104470944A (zh) 2015-03-25
JP2015519345A (ja) 2015-07-09
US20160083436A1 (en) 2016-03-24
BR112014029409A2 (https=) 2017-08-15
IL235808A (en) 2017-10-31
EA201590136A1 (ru) 2016-02-29
JP7166081B2 (ja) 2022-11-07
EP2855509A4 (en) 2016-01-13
WO2013177398A3 (en) 2014-03-27
HK1209134A1 (en) 2016-03-24
US20180009854A1 (en) 2018-01-11
BR112014029409B1 (pt) 2022-11-29
EP2855509B1 (en) 2018-05-02
AU2013266215A1 (en) 2014-12-04
PT2855509T (pt) 2018-08-03
MX355041B (es) 2018-03-28
MX2014014384A (es) 2015-05-11
JP2018171063A (ja) 2018-11-08
ES2670442T3 (es) 2018-05-30

Similar Documents

Publication Publication Date Title
US10280200B2 (en) Non-natural consensus albumin binding domains
US9260496B2 (en) Fibronectin based scaffold domain proteins that bind IL-23
KR102461666B1 (ko) 혈청 알부민 결합 피브로넥틴 iii 형 도메인
KR20220113492A (ko) 변경된 표면 잔기를 갖는 설계된 안키린 반복 도메인
CN107001438A (zh) 白细胞介素‑15组合物及其用途
CN105477641A (zh) 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途
WO2012171541A1 (en) Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
WO2013186329A1 (en) Human fusion proteins comprising single chain tnfalpha and targeting domains
Baumann et al. Identification of a potential modification site in human stromal cell‐derived factor‐1
HK1209134B (en) Non-natural consensus albumin binding domains
KR20240035847A (ko) 인간 파이브로넥틴 유형 iii 단백질 스캐폴드
EA045108B1 (ru) Выделенный искусственный альбумин-связывающий домен и содержащий его слитый белок
WO2021195177A1 (en) Qty fc fusion water soluble receptor proteins
HK40006036B (en) Serum albumin-binding fibronectin type iii domains

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180504

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241225

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241225

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241225

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401